Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy in First Head-to-Head Study -- WSJ

WSJ1minutes ago

Express News | Lilly: At 72 Weeks, Zepbound Beat Wegovy on Both Primary Endpoint, All Five Key Secondary Endpoints in Trial

Reuters1minutes ago

Express News | Lilly's Zepbound (Tirzepatide) Superior to Wegovy (Semaglutide) in Head-to-Head Trial Showing an Average Weight Loss of 20.2% Vs. 13.7%

Reuters1minutes ago

Express News | Lilly: In Phase 3B Trial, Zepbound Provided a 47% Greater Relative Weight Loss Vs Wegovy

Reuters1minutes ago

Express News | Lilly: In Phase 3B Trial, Participants Using Zepbound Lost 50.3 Lbs. (22.8 Kg) and Participants on Wegovy Lost 33.1 Lbs. (15.0 Kg)

Reuters1minutes ago

Express News | Lilly: Commonly Reported Adverse Events in Surmount-5 for Zepbound & Wegovy Were Gastrointestinal-Related, Generally Mild to Moderate in Severity

Reuters1minutes ago